ViaCyte to study PEC-Direct in international clinical trial for type 1 diabetes

US-based regenerative medicine firm ViaCyte has obtained approval for its investigational new drug (IND) application from both the US Food and Drug Administration and Health Canada to initiate a clinical trial for investigating PEC-Direct in patients …
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news